Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
How do you decide on first line treatment for a patient with metastatic colon cancer with dMMR, a HER2 mutation and no mutations in KRAS or BRAF?
Related Questions
How do you manage maintenance for BRAF V600E-mutated metastatic colon cancer responding to FOLFOX + encorafenib + cetuximab (BREAKWATER) in the first line?
Should atezolimab and chemotherapy be considered for stage III dMMR colon cancer with BRAF mutation?
Would you add pembrolizumab to FOLFOX in first line metastatic gastric adenocarcinoma with CPS 0 but high TMB (12)?
Under what circumstances do you give chemotherapy for a nondiagnostic pancreas biopsy that is suspicious for adenocarcinoma?
What are your top takeaways in GI Cancers from ESMO 2025?
Would you add immunotherapy to FOLFOX if the patient is not a FLOT candidate for neoadjuvant gastric cancer, extrapolating data from the MATTERHORN study?
Would you recommend adjuvant chemotherapy for a Stage II colon cancer patient who has negative ctDNA but presented with obstruction?
In patients with unresectable, liver-limited neuroendocrine tumors (NETs), what clinical or radiographic criteria guide your decision to prioritize systemic therapy over locoregional approaches?
What is the optimal systemic therapy for metastatic Gastric Adenocarcinoma with Enteroblastic Differentiation (GAED)?
How long would you continue atezolizumab/bevacizumab in a patient with HCC who is having a prolonged response with stable disease?
